Squarepoint
FLNA

Squarepoint’s Filana Therapeutics FLNA Stock Holding History

Squarepoint’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-47,000
Closed -$111K – 5304
2024
Q4 		$111K Buy
+47,000
New +$825K ﹤0.01% 4674

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Squarepoint's FLNA Position: Q2 2026 in Review

Squarepoint opened a new position in Filana Therapeutics (FLNA) in Q2 2026: 318,380 shares worth $379K. The stake represents ﹤0.01% of the portfolio and ranks #3651 among its holdings. This is a return to the name: Squarepoint previously reported a position in FLNA as recently as Q3 2025.

Squarepoint first reported a position in FLNA in Q2 2015 and has held it in 15 quarters since. The position peaked at $2.33M in Q1 2021. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Squarepoint held 318,380 shares of Filana Therapeutics worth $379K as of Q2 2026.
  • Filana Therapeutics was a new Squarepoint position in Q2 2026.
  • Filana Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3651 holding.
  • Squarepoint first reported a position in Filana Therapeutics in Q2 2015 and has held it in 15 quarters since.
  • Squarepoint's Filana Therapeutics position peaked at $2.33M in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.